$TELO

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data showing that Telomir-Zn significantly improved survival and multiple endpoints in a Wilson's disease model. The study, published in Advances in Redox Research, demonstrated that Telomir-Zn reduced oxidative stress, hepatic copper burden, and tissue degeneration, while improving liver biomarkers and locomotor function. These findings support Telomir-Zn's biological activity in Wilson's disease and its broader mechanistic relevance across other diseases involving oxidative stress and dysregulated metal homeostasis, including Triple-Negative Breast Cancer.